Navigation Links
Novel bee venom derivative forms a nanoparticle 'smart bomb' to target cancer cells
Date:8/2/2010

The next time you are stung by a bee, here's some consolation: a toxic protein in bee venom, when altered, significantly improves the effectiveness liposome-encapsulated drugs or dyes, such as those already used to treat or diagnose cancer. This research, described in the August 2010 print issue of the FASEB Journal (http://www.fasebj.org), shows how modified melittin may revolutionize treatments for cancer and perhaps other conditions, such as arthritis, cardiovascular disease, and serious infections.

"This type of transporter agent may help in the design and use of more personalized treatment regimens that can be selectively targeted to tumors and other diseases," said Samuel A. Wickline, Ph.D., a researcher involved in the work from the Consortium for Translational Research in Advanced Imaging and Nanomedicine (C-TRAIN) at the Washington University School of Medicine in St. Louis, Missouri.

To make this discovery, Wickline and colleagues designed and tested variations of the melittin protein to derive a stable compound that could be inserted into liposomal nanoparticles and into living cells without changing or harming them. They then tested the ability of this protein, or "transporter agent," to attach to different therapeutic compounds and enhance drug therapy without causing harmful side effects. In addition, their results suggest that the base compound which is used to create the transporter agent may improve tumor therapy as well.

"Our journal is abuzz in a hive of bee-related discoveries. Just last month, we published research showing for the first time how honey kills bacteria. This month, the Wickline study shows how bee venom peptides can form "smart bombs" that deliver liposomal nanoparticles directly to their target, without collateral damage," said Gerald Weissmann, M.D., Editor-in-Chief of the FASEB Journal.


'/>"/>

Contact: Cody Mooneyhan
cmooneyhan@faseb.org
301-634-7104
Federation of American Societies for Experimental Biology
Source:Eurekalert

Page: 1

Related biology news :

1. Scientists identify novel inhibitor of human microRNA
2. Conaway Lab identifies novel mechanism for regulation of gene expression
3. LIAI launches new division to look at novel approaches to heart disease and inflammation
4. Childrens National researchers develop novel anti-tumor vaccine
5. Cold Spring Harbor Laboratory scientists trace a novel way cells are disrupted in cancer
6. Novel publishing approach puts textbook in more hands
7. GEN reports on novel tools for deciphering biological networks
8. UT Southwestern researcher awarded Gates Foundation grant for novel vaccine development
9. 3-substituted indolones as novel therapeutic compounds for neurodegenerative conditions
10. Corn researchers discover novel gene shut-off mechanisms
11. A novel target for therapeutics against Staph infection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... 2015 The report "Multi-Factor Authentication (MFA) ... Application (Travel & Immigration, Government, Banking, Defense, Commercial Security, ... 2020", published by MarketsandMarkets, Multi-Factor Authentication Market is expected ... a CAGR of 17.7% between 2015 and 2020. ... igures spread through 169 P ages ...
(Date:8/24/2015)... South Africa , August 24, 2015 ... Germany ,s largest biometrics manufacturer DERMALOG and its ... with the "2015 African Biometrics Company of the Year Award". ... Nigeria .   -Cross reference: ... http://www.presseportal.de/nr/8896 - On Thursday evening, in ...
(Date:8/20/2015)... 20, 2015 The wearable technology market ... active and healthy. However, wearable technology has the ... to help improve diagnostic capabilities and therapeutic outcomes. ... Wearable Technologies Conference 2015 , where ... wearables in healthcare.    "Over the ...
Breaking Biology News(10 mins):Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 2Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 3Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 4Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 5Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 2Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 3Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3
... -- Sequella, Inc., a clinical-stage biopharmaceutical company focused ... potential, announced today that the U.S. Food and ... (EMEA) independently reviewed Sequella lead drug compound, SQ109, ... for the treatment of tuberculosis. SQ109 shows excellent ...
... October 22, 2007 (TORONTO) Height may point to ... released by the Centre for Addiction and Mental Health ... on average than males without a sexual attraction to ... A Journal of Research and Treatment, suggests that pedophiles ...
... collaboration, more than 200 medical and scientific journals ... relationship between poverty and human development. The initiative, ... presentations on seven of the journal articles which ... of Health on Monday, October 22, 2007. ...
Cached Biology News:Sequella receives US and EU orphan drug status for SQ109 for the treatment of TB 2Sequella receives US and EU orphan drug status for SQ109 for the treatment of TB 3200 journals join in theme issues on poverty and human development 2200 journals join in theme issues on poverty and human development 3200 journals join in theme issues on poverty and human development 4200 journals join in theme issues on poverty and human development 5
(Date:9/2/2015)... , Sep. 02, 2015 ... addition of Jain PharmaBiotech,s new report "Gene Therapy ... The markets for gene therapy are difficult ... therapy product and it is marketed in ... estimated for the years 2014-2024. The estimates are based ...
(Date:9/2/2015)... ... 02, 2015 , ... Drug companies increasingly are adopting a ... reveals in its new report that the U.S. will generate the greatest demand ... the most market demand. , BCC Research examines plant-derived drugs in its ...
(Date:9/2/2015)... Sept. 2, 2015 Aytu BioScience, Inc. (OTCQB: ... for urological and related conditions, announced today that it ... placement convertible note financing, raising a total of $5.175 ... $3.175 million. Josh Disbrow , ... private placement are intended to be used to conduct ...
(Date:9/2/2015)... , September 2, 2015 BiondVax ... of the National Institute of Allergy and Infectious Diseases (NIAID), ... the Department of Health and Human Services (HHS), to launch ... the United States in the 2015-16 timeframe. ... vaccine candidate, Multimeric-001 (M-001), as a primer vaccine, which would ...
Breaking Biology Technology:Global Gene Therapy Market Study 2015-2024 - Technologies, Markets and Companies Analysis 2Plant-derived Compounds Poised to Assume Greater Role in Global Drug Markets, According to BCC Research 2Plant-derived Compounds Poised to Assume Greater Role in Global Drug Markets, According to BCC Research 3Aytu BioScience Completes $5.175 Million Private Placement 2Aytu BioScience Completes $5.175 Million Private Placement 3BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 2BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 3
... ... Akt/mTOR inhibitor -, JAMAICA ... has presented three presentations at the 2008,annual meeting of the ... P529 is a non-steroidal, synthetic, small molecule dual acting,anti-angiogenic ...
... DEERFIELD, Ill., April 15 , What and ... CHICAGO (Carotid,intima-media tHICkness in Atherosclerosis using pioGlitazOne) published,today ... thickness (CIMT) with ACTOS(R) (pioglitazone HCl) was,associated with ... when compared to glimepiride., The increased effect ...
... /PRNewswire/ - The acceptance of Peros, oral,delivery platform ... achievement by Benchmark Biolabs, a full service,biopharmaceutical product ... oversees the operation and,management of the Peros production ... biotechnology campus in Lincoln, NE., By obtaining ...
Cached Biology Technology:Paloma Pharmaceuticals to Present at the American Association for Cancer Research 2Paloma Pharmaceuticals to Present at the American Association for Cancer Research 3Paloma Pharmaceuticals to Present at the American Association for Cancer Research 4New Data Published in Circulation Showed an Increase in HDL Cholesterol Levels with ACTOS(R) (pioglitazone HCl) 2New Data Published in Circulation Showed an Increase in HDL Cholesterol Levels with ACTOS(R) (pioglitazone HCl) 3Another industry first enabled by Benchmark Biolabs - Peros' oral delivery platform and vaccine facility licensed by the USDA 2
... Incubator is a compact benchtop and ... microprocessor controller with a large display ... agitation speed. Air circulation inside to ... Temperature can be easily calibrated from ...
... is a compact benchtop and stackable ... controller with a large display screen ... speed. Air circulation inside to evenly ... can be easily calibrated from the ...
... Nonanoyl-N-methylglucamide White solid. ... be readily removed by dialysis. Useful ... ≥98% by HPLC. Absorbance (10%, ... 2 O. CMC 19 - 25 ...
...
Biology Products: